NEW YORK (

TheStreet

) --

Biogen Idec

(Nasdaq:

BIIB

) hit a new 52-week high Thursday as it is currently trading at $147.52, above its previous 52-week high of $147.49 with 658,840 shares traded as of 1:10 p.m. ET. Average volume has been 1.2 million shares over the past 30 days.

Biogen Idec has a market cap of $33.41 billion and is part of the

health care

sector and

drugs

industry. Shares are up 30.3% year to date as of the close of trading on Wednesday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 25.3, below the average drugs industry P/E ratio of 27.4 and above the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

TheStreet Ratings rates Biogen Idec as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full

Biogen Idec Ratings Report

.

See all

52-week high stocks

or get investment ideas from our

investment research center

.

null